Abstract:I read with great interest the article by Das et al. Although presence of nonalcoholic fatty liver (NAFL) in nonobese individuals is a fairly common observation in India, this is the first such scientific documentation for the same. However, I would like to make a few points in this regard. First, NAFL constitutes a wide spectrum of liver disease with varied natural history extending from simple steatosis to more sinister variants, i.e., nonalcoholic steatohepatitis (NASH) and fibrosis/cirrhosis. Only a proportion of NAFL actually progresses to the more sinister end of this spectrum. Therefore, instead of a blanket focus on NAFL, it would be more appropriate to identify the subset of patients with NAFL who are more likely to progress to NASH. In this regard, the authors have defined ‘‘potentially significant NAFL’’ as ‘‘subjects with definite NAFL who had persistently elevated ALT (>40 IU/L)’’. However, even in this study only one-third of these subjects with ‘‘potentially significant NAFL’’ were found to have NASH on liver biopsy, which means elevated ALT alone is not a good enough marker of ‘‘potentially significant’’ NAFL. A full panel of noninvasive markers of liver fibrosis would be more appropriate to define this subset and save costly and/or potentially harmful procedures like liver biopsy or computed tomography scans for them. Second, although the authors have claimed to have excluded people with alcohol consumption from this study, this population in context comes largely from a tribal background who indulges in many nonconventional forms of ethanol consumption, e.g., mahua flower (Madhuca longifolia). It would be interesting to know if the authors have ruled out those possibilities as well. Third, risk of NAFL is undoubtedly associated with obesity and metabolic syndrome and has been traditionally associated with more affluent living standards. In the current study too, even nonobese subjects with NAFL had worse metabolic parameters and higher income than their age-matched and sex-matched counterparts who did not have NAFL. Nevertheless, coexistence of intrauterine and neonatal malnutrition and the development of obesity, type 2 diabetes, and related comorbidities have been confirmed in a number of studies in humans and animal models. Moreover, it has been shown that, in humans, the intrahepatic lipid content increase following starvation also may be due to reduced apolipoprotein B-100 production and hepatic lipid export, and/or impaired mitochondrial function; this could have implications for exacerbations of steatohepatitis that is sometimes seen with rapid weight loss, anorexia nervosa, and parenteral nutrition. Therefore, in contrast to the popular view, malnutrition rather than obesity at different stages of life may well be an explanation for pathogenesis of NAFL in this predominantly poor population.

An emerging probiotic with liver health benefits for smokers

Gut bacteria alleviate smoking-related NASH by degrading gut nicotine

Lactobacillus Casei Yrl577 Ameliorates Markers Of Non-Alcoholic Fatty Liver And Alters Expression Of Genes Within The Intestinal Bile Acid Pathway

Lactobacillus Casei YRL577 Combined with Plant Extracts Reduce Markers of Non-Alcoholic Fatty Liver Disease in Mice

Nicotine Enhances Invasion and Metastasis of Human Colorectal Cancer Cells Through the Nicotinic Acetylcholine Receptor Downstream P38 MAPK Signaling Pathway.

Is Cigarette Smoking an Independent Risk Factor or a Cofactor for Nonalcoholic Fatty Liver Disease?

Nicotine aggravates high-fat diet-induced non-alcoholic fatty liver disease in mice via inhibition of CISD3

An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease

Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.

The effects of cigarettes and alcohol on intestinal microbiota in healthy men

Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome

Coprococcus protects against high-fat diet-induced nonalcoholic fatty liver disease in mice

Probiotics: A possible specific liver drug for non-alcoholic fatty liver disease

Nicotine exacerbates liver damage in a mice model of Ehrlich ascites carcinoma through shifting SOD/NF-κB/caspase-3 pathways: ameliorating role of Chlorella vulgaris

Role of Probiotics in Gut Microbiome and Metabolome in Non-Alcoholic Fatty Liver Disease Mouse Model: A Comparative Study

Study on the Regulatory Mechanism of Niacin Combined with B. animalis F1-7 in Alleviating Alcoholic Fatty Liver Disease by Up-Regulating GPR109A

Bifidobacterium-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis

Nanoparticles alleviate non-alcoholic steatohepatitis via ER stress sensor-mediated intestinal barrier damage and gut dysbiosis

Probiotics and Non-Alcoholic Fatty Liver Disease: Unveiling the Mechanisms of Lactobacillus plantarum and Bifidobacterium bifidum in Modulating Lipid Metabolism, Inflammation, and Intestinal Barrier Integrity

When smoke meets gut: deciphering the interactions between tobacco smoking and gut microbiota in disease development

Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics